MyHealthChecked (MHC) Competitors GBX 18.17 +1.07 (+6.23%) As of 01/21/2025 11:09 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitors MHC vs. BELL, POLX, IHC, AVO, RUA, SUN, DEMG, SN, MXCT, and NIOXShould you be buying MyHealthChecked stock or one of its competitors? The main competitors of MyHealthChecked include Belluscura (BELL), Polarean Imaging (POLX), Inspiration Healthcare Group (IHC), Advanced Oncotherapy (AVO), RUA Life Sciences (RUA), Surgical Innovations Group (SUN), Deltex Medical Group (DEMG), Smith & Nephew (SN), MaxCyte (MXCT), and NIOX Group (NIOX). These companies are all part of the "medical devices" industry. MyHealthChecked vs. Belluscura Polarean Imaging Inspiration Healthcare Group Advanced Oncotherapy RUA Life Sciences Surgical Innovations Group Deltex Medical Group Smith & Nephew MaxCyte NIOX Group Belluscura (LON:BELL) and MyHealthChecked (LON:MHC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, community ranking, valuation, analyst recommendations, risk and dividends. Do insiders & institutionals have more ownership in BELL or MHC? 6.3% of Belluscura shares are owned by institutional investors. Comparatively, 3.1% of MyHealthChecked shares are owned by institutional investors. 56.3% of Belluscura shares are owned by insiders. Comparatively, 53.6% of MyHealthChecked shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Is BELL or MHC more profitable? Belluscura has a net margin of 0.00% compared to MyHealthChecked's net margin of -11.06%. MyHealthChecked's return on equity of -12.92% beat Belluscura's return on equity.Company Net Margins Return on Equity Return on Assets BelluscuraN/A -85.01% -43.53% MyHealthChecked -11.06%-12.92%-8.18% Does the MarketBeat Community prefer BELL or MHC? Belluscura and MyHealthChecked both received 0 outperform votes by MarketBeat users. CompanyUnderperformOutperformBelluscuraN/AN/AMyHealthCheckedN/AN/A Which has better earnings & valuation, BELL or MHC? MyHealthChecked has higher revenue and earnings than Belluscura. MyHealthChecked is trading at a lower price-to-earnings ratio than Belluscura, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBelluscura£1.80M7.80-£18.60M-£0.10-83.40MyHealthChecked£9.39M1.01-£1.04M-£0.02-908.30 Does the media refer more to BELL or MHC? In the previous week, Belluscura's average media sentiment score of 0.00 equaled MyHealthChecked'saverage media sentiment score. Company Overall Sentiment Belluscura Neutral MyHealthChecked Neutral Which has more risk & volatility, BELL or MHC? Belluscura has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500. Comparatively, MyHealthChecked has a beta of 1.37, meaning that its share price is 37% more volatile than the S&P 500. SummaryMyHealthChecked beats Belluscura on 6 of the 11 factors compared between the two stocks. Get MyHealthChecked News Delivered to You Automatically Sign up to receive the latest news and ratings for MHC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MHC vs. The Competition Export to ExcelMetricMyHealthCheckedMedical Devices IndustryMedical SectorLON ExchangeMarket Cap£9.45M£2.27B£5.40B£2.04BDividend YieldN/A2.37%5.37%5.16%P/E Ratio-908.30218.0388.971,926.65Price / Sales1.01206.161,285.79384,006.48Price / Cash1.7815.3836.6029.21Price / Book1.304.394.963.08Net Income-£1.04M£77.46M£117.96M£183.60M7 Day Performance16.30%3.71%2.58%3.09%1 Month Performance71.95%11.03%3.53%3.42%1 Year Performance61.48%23.33%27.05%165.41% MyHealthChecked Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MHCMyHealthCheckedN/AGBX 18.17+6.2%N/A+61.5%£9.45M£9.39M-908.3016Gap DownHigh Trading VolumeBELLBelluscuraN/AGBX 8.95-0.6%N/A-52.3%£15.06M£1.80M-89.4524Gap DownPOLXPolarean ImagingN/AGBX 1.24-0.1%N/A-85.2%£14.96M£1.87M-61.8028Gap UpIHCInspiration Healthcare GroupN/AGBX 13+3.6%N/A-71.8%£11.66M£34.30M-92.86224High Trading VolumeAVOAdvanced OncotherapyN/AN/AN/AN/A£9.50MN/A-25.003,900Gap DownRUARUA Life SciencesN/AGBX 11.60-3.3%N/A-1.1%£7.20M£2.19M-290.0048SUNSurgical Innovations GroupN/AGBX 0.51-10.8%N/A-16.2%£4.71M£12.54M-21.1180Gap UpHigh Trading VolumeDEMGDeltex Medical GroupN/AGBX 0.07+2.8%N/A-78.2%£1.39M£1.78M-5.7537News CoverageGap DownHigh Trading VolumeSNSmith & Nephew3.6637 of 5 starsGBX 988-1.6%GBX 3,956.20+300.4%-6.5%£8.62B£5.64B3,659.2618,452High Trading VolumeMXCTMaxCyteN/AGBX 387+5.2%N/A-2.1%£406.70M£45.44M-1,488.4680Gap UpNIOXNIOX GroupN/AGBX 60.20+3.1%N/A+6.7%£255.33M£39M3,010.0092 Related Companies and Tools Related Companies Belluscura Competitors Polarean Imaging Competitors Inspiration Healthcare Group Competitors Advanced Oncotherapy Competitors RUA Life Sciences Competitors Surgical Innovations Group Competitors Deltex Medical Group Competitors Smith & Nephew Competitors MaxCyte Competitors NIOX Group Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (LON:MHC) was last updated on 1/22/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump currency shock imminentTrump's Quiet $1.9 Trillion Move Against the Fed A small army of Americans, with Trump's support, has launc...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredThe Crypto Secret Wall Street Doesn’t Want You to KnowThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MyHealthChecked PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share MyHealthChecked With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
